Cervical cancer is the second most common cancer after breast cancer to affect women aged 15–44 years in the European Union. Each year, there are around 33 000 cases of cervical cancer in the EU, and 15 000 deaths. The primary cause of cervical cancer is a persistent infection of the genital tract by some specific types of human papillomavirus (HPV). HPV is present in most cases of cervical lesions, which can further develop into cancer.¹

Vaccination rates and the incidence of cervical adenocarcinoma are both on the rise, making HPV genotype testing an important tool to help stratify risk and guide patient management. High-risk HPV genotypes 16, 18 account for 70% of cervical cancer worldwide. Tianlong’s Human Papillomavirus (HPV) Nucleic Acid Detection Kit is a qualitative in vitro test for detection of 18 high-risk HPV types (HPV 16,18,26,31,33,35,39,45,51,52,53, 56,58,59,66,68,73 and 82), which can specifically identify types of HPV 16 and HPV 18 while concurrently detecting the rest of other high-risk types.

Features

• High Precision:
  The coefficient of variation of the Ct values (CV%) is less than 5%
• More accurate:
  Collocating with Tianlong extraction reagent makes your experiment results more accurate
• Internal Control:
  The use of internal control system in the kit can effectively prevent false negative results
• User-friendly:
  Applicable in instruments with FAM 、HEX/VIC、CY5 and TEXAS RED/ROX channels
• Concurrently detects remaining 16 HPV genotypes:
  26,31,33,35,39,45,51,52,53,56,58,59,66,68,73,82 Positive or Negative Pooled Result

Click here for more information and to download the product brochure, or use the Request Information button to connect directly with Tianlong.

Source
1.    www.ecdc.europa.eu/en/news-events/january-cervical-cancer-awareness-month